SCHEMBL2221101

SCHEMBL2221101

COC(=O)CCC(=O)CCl

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 5/20 0.65
LMNA P02545 3/20 0.58
KDM4E B2RXH2 1/20 0.58
CA12 O43570 3/20 0.46
CA14 Q9ULX7 3/20 0.46
ALDH1A1 P00352 4/20 0.45
KMT2A Q03164 2/20 0.45
HSD17B10 Q99714 2/20 0.45
MAPT P10636 1/20 0.45
HTT P42858 1/20 0.45
MEN1 O00255 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.40
MGAM O43451 1/20 0.40
GAA P10253 1/20 0.40
SI P14410 1/20 0.40
MGAM2 Q2M2H8 1/20 0.40
CA7 P43166 1/20 0.37
CA9 Q16790 1/20 0.37
RECQL P46063 1/20 0.37
HPGD P15428 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9848297 0.86 TSHR (0.61) TSHRLMNAKDM4ECA12CA14
SCHEMBL1518251 0.86 TSHR (0.68) TSHRLMNAKDM4ECA12CA14
SCHEMBL25187 0.84 TSHR (0.81) TSHRLMNAKDM4ECA12CA14
SCHEMBL10481290 0.84 TSHR (0.81) TSHRLMNAKDM4ECA12CA14
SCHEMBL10021631 0.83 TSHR (0.62) TSHRLMNAKDM4ECA12CA14
SCHEMBL10481289 0.81 TSHR (0.77) TSHRLMNAKDM4ECA12CA14
Dimethyl Succinate SCHEMBL10213 0.81 TSHR (1.00) TSHRLMNAKDM4ECA12CA14
Dimethyl Succinate SCHEMBL28054469 0.81 TSHR (1.00) TSHRLMNAKDM4ECA12CA14
SCHEMBL11219823 0.79 ALDH1A1 (0.43) TSHRLMNAKDM4EALDH1A1
SCHEMBL6560703 0.79 TSHR (0.72) TSHRLMNAKDM4ECA12CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107857740-A The synthetic method of the thiazolyl acetic acid of 2 sulfydryl of Cefodizime Sodium intermediate, 4 methyl 5 山东金城医药化工有限公司 2018-03-30 CN claimed
US-7339073-B2 Method for obtaining 5-halogenolaevulinic acid alkyl esters ALDENKORTT SVEN 2008-03-04 US claimed
US-7319164-B2 5-azido-laevulinic acid, method for the production thereof and its use ALDENKORTT SVEN 2008-01-15 US claimed
EP-1353900-B1 5-AZIDO-LAEVULINIC ACID, METHOD FOR THE PRODUCTION THEREOF AND ITS USE ALDENKORTT SVEN (DE) 2006-10-04 EP claimed
US-20060086443-A1 5-azido-laevulinic acid, method for the production thereof and its use ALDENKORTT SVEN 2006-04-27 US claimed
US-20050070727-A1 Method for obtaining 5-halogenolaevulinic acid alkyl esters ALDENKORTT DR SVEN (DE) 2005-03-31 US claimed
EP-3705480-B1 CLASS OF AMINO-SUBSTITUTED NITROGEN-CONTAINING FUSED RING COMPOUNDS, PREPARATION METHOD THEREFOR, AND USE THEREOF SHANGHAI RINGENE BIOPHARMA CO LTD (CN) 2024-02-28 EP disclosed
CN-109721600-B Nitrogen-containing fused ring compounds and preparation method and application thereof 上海凌达生物医药有限公司 2021-04-27 CN disclosed
CN-109721599-B Amino-substituted nitrogen-containing fused ring compound and preparation method and application thereof 上海凌达生物医药有限公司 2020-12-15 CN disclosed
US-20200347061-A1 CLASS OF AMINO-SUBSTITUTED NITROGEN-CONTAINING FUSED RING COMPOUNDS, PREPARATION METHOD THEREFOR, AND USE THEREOF SHANGHAI RINGENE BIOPHARMA CO., LTD. (CN) 2020-11-05 US disclosed
EP-3705480-A1 CLASS OF AMINO-SUBSTITUTED NITROGEN-CONTAINING FUSED RING COMPOUNDS, PREPARATION METHOD THEREFOR, AND USE THEREOF Rudong Ringene Pharmaceuticals, Co. Ltd (CN) 2020-09-09 EP disclosed
CN-107857740-A The synthetic method of the thiazolyl acetic acid of 2 sulfydryl of Cefodizime Sodium intermediate, 4 methyl 5 山东金城医药化工有限公司 2018-03-30 CN disclosed
CN-107857740-A The synthetic method of the thiazolyl acetic acid of 2 sulfydryl of Cefodizime Sodium intermediate, 4 methyl 5 山东金城医药化工有限公司 2018-03-30 CN disclosed
EP-1461304-A2 METHOD FOR OBTAINING 5-HALOGENOLAEVULINIC ACID ALKYL ESTERS Mariotti, Antonia (DE) 2004-09-29 EP disclosed
EP-1353900-A2 5-AZIDO-LAEVULINIC ACID, METHOD FOR THE PRODUCTION THEREOF AND ITS USE Aldenkortt, Sven (DE) 2003-10-22 EP disclosed
WO-2003045895-A3 METHOD FOR OBTAINING 5-HALOGENOLAEVULINIC ACID ALKYL ESTERS MARIOTTI ANTONIA (DE) 2003-09-18 WO disclosed
WO-2003045895-A2 METHOD FOR OBTAINING 5-HALOGENOLAEVULINIC ACID ALKYL ESTERS MARIOTTI ANTONIA (DE) 2003-06-05 WO disclosed
WO-2002053532-A3 5-AZIDO-LAEVULINIC ACID, METHOD FOR THE PRODUCTION THEREOF AND ITS USE ALDENKORTT SVEN (DE) 2003-03-13 WO disclosed
WO-2002053532-A2 5-AZIDO-LAEVULINIC ACID, METHOD FOR THE PRODUCTION THEREOF AND ITS USE ALDENKORTT SVEN (DE) 2002-07-11 WO disclosed
US-4000275-A BENZIMIDAZO(2,1-B) QUINAZOLIN-12(6H)ONES ELI LILLY AND COMPANY (US) 1976-12-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200347061-A1 CLASS OF AMINO-SUBSTITUTED NITROGEN-CONTAINING FUSED RING COMPOUNDS, PREPARATION METHOD THEREFOR, AND USE THEREOF FGFR4, FGFR3, FGFR1 TSHR 4079/4885LMNA 4179/4885KDM4E 729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.